

THIS CA UPDATE HAS BEEN SENT TO THE FOLLOWING:**COUNTIES:**

- Imperial
- Riverside/San Bernardino
- Los Angeles
- Orange
- Sacramento
- San Diego

LINES OF BUSINESS:

- Molina Medi-Cal Managed Care
- Molina Medicare Options Plus
- Molina Dual Options Cal MediConnect Plan (Medicare-Medicaid Plan)
- Molina Marketplace (Covered CA)

PROVIDER TYPES: **Medical Group/ IPA/MSO****Primary Care**

- IPA/MSO
- Directs

Specialists

- Directs
- IPA

 Hospitals**Ancillary**

- CBAS
- SNF/LTC
- DME
- Home Health
- Other

FOR QUESTIONS CALL**PROVIDER SERVICES:**

(888) 562-5442, Extension:

Los Angeles/Orange Counties

X123017

Riverside/San Bernardino Counties

X120613

Sacramento County

X121599

San Diego County

X121735

Imperial County

X125682

Medi-Cal Drug Utilization Review (DUR) Educational Article – 2019 New Global Guidelines for the Treatment of Asthma

This is an advisory notification to Molina Healthcare of California (MHC) network providers regarding New Global Guidelines for the Treatment of Asthma.

The World Health Organization (WHO) and the National Heart, Lung, and Blood Institute (NHLBI) established the Global Initiative for Asthma (GINA) in 1993 in order to increase awareness about asthma among health professionals, public health authorities, and the community, and to improve asthma prevention and management through a coordinated worldwide effort. The GINA Scientific Committee conducts a twice-yearly cumulative review of the literature and has published the GINA report annually since 2002. In 2019, GINA undertook a comprehensive review of the risks and consequences of commencing asthma treatment with short-acting β_2 -agonists (SABAs) alone and evaluated the impact on asthma exacerbations and deaths of any form of inhaled corticosteroid (ICS) in mild asthma.

The 2019 GINA report Global Strategy for Asthma Management and Prevention Recommendations

There is sufficient evidence to recommend that adults and adolescents with asthma should not be treated with SABAs alone. Instead, they should receive either symptom-driven (in mild asthma) or daily ICS-containing treatment in order to reduce risk of serious exacerbations and asthma-related death. The Molina formulary includes the following ICS choices: Qvar Redihaler, Arnuity Ellipta, Flovent HFA 44mcg or 110mcg (approved for 11 years old and under) and budesonide inhalation suspension 0.25mg/2ml or 0.5mg/2ml (approved for 9 years old and under).

For more information regarding New Global Guidelines for the Treatment of Asthma, please visit: https://files.medi-cal.ca.gov/pubsdoco/dur/Articles/dured_30014.pdf

QUESTIONS

If you have any questions regarding the notification, please contact your Molina Provider Services Representative at (888) 562-5442. Please refer to the extensions to the left.